Rutgers Emiel J T, Meijnen Philip, Bonnefoi Hervé
Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Breast Cancer Res. 2004;6(4):165-9. doi: 10.1186/bcr906. Epub 2004 Jun 16.
The present clinical trial update consists of a review of two of eight current studies (the 10981-22023 AMAROS trial and the 10994 p53 trial) of the European Organization for Research and Treatment of Cancer Breast Cancer Group, as well as a preview of the MIND-ACT trial. The AMAROS trial is designed to prove equivalent local/regional control for patients with proven axillary lymph node metastasis by sentinel node biopsy if treated with axillary radiotherapy instead of axillary lymph node dissection, with reduced morbidity. The p53 trial started to assess the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane regimen versus a nontaxane regimen.
本次临床试验更新内容包括对欧洲癌症研究与治疗组织乳腺癌小组八项当前研究中的两项（10981 - 22023 AMAROS试验和10994 p53试验）进行回顾，以及对MIND - ACT试验的预览。AMAROS试验旨在证明，对于经前哨淋巴结活检证实有腋窝淋巴结转移的患者，若采用腋窝放疗而非腋窝淋巴结清扫术进行治疗，局部/区域控制效果相当，且发病率降低。p53试验开始前瞻性随机将局部晚期/炎性或可手术的大乳腺癌患者分为紫杉烷方案组和非紫杉烷方案组，使用酵母中的功能测定法评估p53的潜在预测价值。
